Oncoquest-L (Non-Hodgkin's lymphoma vaccine)
/ R2T Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 23, 2021
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
(clinicaltrials.gov)
- P2; N=30; Not yet recruiting; Sponsor: XEME Biopharma Inc.; Trial completion date: Jan 2023 ➔ Jun 2026; Trial primary completion date: Jan 2022 ➔ Jun 2024
Clinical • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CTCs
April 23, 2020
"Dual Industrial set to acquire OncoQuest's clinical and preclinical immunotherapy development assets for $300 million"
(@Cortellis)
January 10, 2019
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
(clinicaltrials.gov)
- P2; N=30; Not yet recruiting; Sponsor: XEME Biopharma Inc.; Trial completion date: Jun 2020 ➔ Jan 2023; Trial primary completion date: May 2020 ➔ Jan 2022
Clinical • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1